Division of Pediatric Cardiology, Department of Cardiology, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA.
Transl Res. 2011 Feb;157(2):92-9. doi: 10.1016/j.trsl.2010.11.002. Epub 2010 Dec 13.
Iron cardiomyopathy in ß-thalassemia major patients is associated with a vitamin D deficiency. Stores of 25-OH-D3 are markedly reduced, whereas the active metabolite, 1-25-(OH)-D3, is normal or increased. Interestingly, the ratio of 25-OH-D3 to 1-25-(OH)-D3 (a surrogate for parathyroid hormone [PTH]) is the strongest predictor of cardiac iron. Increased PTH and 1-25-OH-D3 levels have been shown to up-regulate L-type voltage-gated calcium channels (LVGCC), the putative channel for cardiac iron uptake. Therefore, we postulate that a vitamin D deficiency increases cardiac iron by altering LVGCC regulation. Hemojuvelin knockout mice were calcitriol treated, PTH treated, vitamin D-depleted, or untreated. Half of the animals in each group received the Ca(2+)-channel blocker verapamil. Mn(2+) was infused to determine LVGCC activity. Hearts and livers were harvested for iron, calcium, and manganese measurements as well as histology. Cardiac iron did not differ among the treatment groups; however, liver iron was increased in vitamin D-depleted animals (P < 0.0003). Cardiac iron levels did not correlate with manganese uptake but were proportional to cardiac calcium levels (r(2) = 0.6; P < 0.0001). Verapamil treatment reduced both cardiac (P < 0.02) and hepatic (P < 0.003) iron levels significantly by 34% and 28%, respectively. The association between cardiac iron and calcium levels was maintained after verapamil treatment (r(2) = 0.3; P < 0.008). Vitamin D depletion is associated with an increase in liver, but not cardiac, iron accumulation. Cardiac iron uptake was strongly correlated with cardiac calcium stores and was significantly attenuated by verapamil, suggesting that cardiac calcium and iron are related.
β-地中海贫血患者的铁性心肌病与维生素 D 缺乏有关。25-羟维生素 D3 的储存量明显减少,而活性代谢产物 1-25-(OH)-D3 则正常或增加。有趣的是,25-羟维生素 D3 与 1-25-(OH)-D3 的比值(甲状旁腺激素 [PTH] 的替代物)是心脏铁的最强预测因子。已显示升高的 PTH 和 1-25-OH-D3 水平可上调 L 型电压门控钙通道(LVGCC),这是心脏铁摄取的假定通道。因此,我们假设维生素 D 缺乏通过改变 LVGCC 调节来增加心脏铁。钙三醇处理、甲状旁腺素处理、维生素 D 缺乏或未处理的血影蛋白敲除小鼠。每组动物的一半接受钙通道阻滞剂维拉帕米治疗。用 Mn2+ 输注来确定 LVGCC 活性。收获心脏和肝脏以进行铁、钙和锰测量以及组织学检查。心脏铁在治疗组之间没有差异;然而,维生素 D 缺乏动物的肝脏铁增加(P < 0.0003)。心脏铁水平与锰摄取无关,但与心脏钙水平成正比(r2 = 0.6;P < 0.0001)。维拉帕米治疗分别显著降低心脏(P < 0.02)和肝脏(P < 0.003)铁水平 34%和 28%。维拉帕米治疗后,心脏铁与钙水平之间的相关性仍然存在(r2 = 0.3;P < 0.008)。维生素 D 缺乏与肝脏铁而非心脏铁蓄积增加有关。心脏铁摄取与心脏钙储存强烈相关,维拉帕米显著减弱,表明心脏钙和铁有关。